Back
47· Steady
Markets2h 22m ago
Enlivex Ltd. announced the issuance of an Australian patent, numbered 2020340629, titled, "THERAPEUTIC APOPTOTIC CELLS FOR TREATMENT OF OSTEOARTHRITIS,” which provides intellectual property protection in Australia through at least 2040.
Nes-Ziona, Israel; Australia
Who
Enlivex Ltd.
What
Enlivex Ltd. announced the issuance of an Australian patent, numbered 2020340629, titled, "THERAPEUTIC APOPTOTIC CELLS FOR TREATMENT OF OSTEOARTHRITIS,” which provides intellectual property protection in Australia through at least 2040.
When
Mon, 15 Jun 2026 12:09:38 GMT · 2h 22m ago
Where
Nes-Ziona, Israel; Australia ·
Why
This patent issuance strengthens Enlivex's global intellectual property position as its Phase 2b clinical program for Allocetra™ advances.
The Frontline Impact
How this affects you
This patent strengthens Enlivex's intellectual property and market position in Australia for its Allocetra™ treatment, potentially enabling broader access to the therapy if clinical trials are successful. For global readers, it signifies progress in the development of new treatments for osteoarthritis, a widespread disabling disease.
Story chain
2 events in this thread- Currently Reading2h 22m agoEnlivex Ltd. announced the issuance of an Australian patent, numbered 2020340629, titled, "THERAPEUTIC APOPTOTIC CELLS FOR TREATMENT OF OSTEOARTHRITIS,” which provides intellectual property protection in Australia through at least 2040.
- Markets2h 22m agoEnlivex announced the issuance of an Australian patent covering the use of Allocetra™ for treating osteoarthritis, providing intellectual property protection in Australia through at least 2040.Open article
Verified Sources & Citations
Credibility ratings reflect the AI ingestion pipeline's assessment of source provenance.